TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine
Brief Summary: The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group
D: Arm Label: Breastfeeding; Type: OTHER; Interventions: Other: Breastfeeding | Arm Label: Breastfeeding Withheld; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding, Breastfeeding Withheld

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine
Brief Summary: The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation
B: Arm Label: Breastfeeding; Type: OTHER; Interventions: Other: Breastfeeding | Arm Label: Breastfeeding Withheld; Type: ACTIVE_COMPARATOR; Interventions: Other: Breastfeeding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding, Breastfeeding Withheld
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group
D: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Brief Summary: RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sometimes after treatment, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether erlotinib is more effective than observation after first-line chemotherapy in treating patients with ovarian cancer, peritoneal cancer, or fallopian tube cancer.

PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works compared to observation in treating patients who have undergone first-line chemotherapy for ovarian cancer, peritoneal cancer, or fallopian tube cancer.


Options:
A: Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: MM-121 (SAR256212) + Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: MM-121, Drug: Paclitaxel | Intervention Type: DRUG; Name: MM-121; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): MM-121 (SAR256212) + Paclitaxel, Paclitaxel
B: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A
C: Arm Label: Lapatinib Oral Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral lapatinib tablets or placebo tablets | Intervention Type: DRUG; Name: Oral lapatinib tablets or placebo tablets; Assigned to Arm(s): Lapatinib Oral Tablets, Placebo Control
D: Intervention Type: DRUG; Name: erlotinib hydrochloride; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Self-care Intervention for Latino Adults With Diabetes
Brief Summary: The purpose of this study is to modify and evaluate a culturally appropriate intervention that is designed to improve diabetes self-care practices by enhancing the self-efficacy, empowerment and diabetes knowledge among Latino adults over the age of 55 years.


Options:
A: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
B: Intervention Type: BEHAVIORAL; Name: Empowerment; Assigned to Arm(s): N/A
C: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm
D: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: UK-500,001; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of UK-500,001 Dry Powder For Inhalation (DPI) In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).
Brief Summary: This initial proof of concept, phase II study aims to assess the safety and efficacy of UK-500,001 for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease.


Options:
A: Intervention Type: DRUG; Name: UK-500,001; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Daliresp; Type: ACTIVE_COMPARATOR; Interventions: Drug: roflumilast | Intervention Type: DRUG; Name: roflumilast; Assigned to Arm(s): Daliresp | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: D-dimer Test to Establish Duration of Anticoagulation After a First Idiopathic Episode of Venous Thromboembolism; the Prospective Randomized "Prolong" Study
Brief Summary: The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain. The present study addresses the possible role of the D-dimer test in assessing the need for continuation of anticoagulation.The study aims at assessing whether D-dimer assay may have a role in guiding the duration of anticoagulation in these patients


Options:
A: Intervention Type: DRUG; Name: Duration of anticoagulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin duration; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sodium warfarin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium warfarin | Intervention Type: DRUG; Name: sodium warfarin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Sodium warfarin; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: Vitamin K antagonist (Coumarin anticoagulants); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Controlled Study of Autologous Bone Marrow-Derived Stem Cell Transfer In Patients With ST-Segment Elevation Myocardial Infarction.
Brief Summary: The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by postinfarction left ventricular (LV) dysfunction.The purpose of this study is to determine whether intracoronary transfer of bone marrow cells will augment left ventricular function recovery of the heart.


Options:
A: Intervention Type: PROCEDURE; Name: bone marrow-derived stem cell transfer; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Arm Label: Late; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Intervention Type: PROCEDURE; Name: intracoronary bone marrow cells infusion; Assigned to Arm(s): Early, Late
C: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo suspension | Intervention Type: OTHER; Name: autologous stem cells; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo suspension; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Management of Superficial Thrombophlebitis
Brief Summary: The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).


Options:
A: Arm Label: 1; Type: N/A; Interventions: Procedure: compression ultrasonography at 3 months | Arm Label: 2; Type: N/A; Interventions: N/A | Intervention Type: PROCEDURE; Name: compression ultrasonography at 3 months; Assigned to Arm(s): 1
B: Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin sodium injection | Intervention Type: DRUG; Name: Dalteparin sodium injection; Assigned to Arm(s): Ibuprofen
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux
D: Arm Label: dalteparin 5000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Arm Label: dalteparin 15000 I.U./24 h s.c.; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 5000 I.U./24 h s.c. | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): dalteparin 15000 I.U./24 h s.c.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Computerised Physician Reminder System to Control Cardiovascular Risk Factors in HIV-infected Patients Receiving Antiretroviral Therapy: A Nested Randomised Controlled Cluster Trial Within the Swiss HIV Cohort Study
Brief Summary: There is growing evidence that antiretroviral therapy (ART) increases the risk of coronary heart disease (CHD) through metabolic side effects, such as dyslipidemia, insulin resistance, and type II diabetes. Prevalence of risk factors for CHD in HIV-infected individuals receiving ART in the Swiss HIV Cohort Study (SHCS) is high. This cluster randomised controlled trial is nested into the SHCS and will investigate whether physicians randomised to the routine provision of risk profiles from their patients receiving ART will improve the management of risk factors in HIV-infected patients compared to control physicians not routinely receiving such information. Risk profiles will be generated by the SHCS data center and provided to clinicians in all study centers.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Outreach Facilitation implementing elements of the Chronic Care Model | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outreach Facilitation implementing elements of the Chronic Care Model; Assigned to Arm(s): intervention
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
C: Arm Label: Case; Type: EXPERIMENTAL; Interventions: Behavioral: Peer Coach Phone Calls, Behavioral: Health Educator Visits, Other: written materials | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: written materials | Intervention Type: BEHAVIORAL; Name: Peer Coach Phone Calls; Assigned to Arm(s): Case | Intervention Type: BEHAVIORAL; Name: Health Educator Visits; Assigned to Arm(s): Case | Intervention Type: OTHER; Name: written materials; Assigned to Arm(s): Case, Control
D: Arm Label: Updated CHD risk profiles; Type: EXPERIMENTAL; Interventions: Behavioral: Updated CHD risk profiles | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Guidelines | Intervention Type: BEHAVIORAL; Name: Updated CHD risk profiles; Assigned to Arm(s): Updated CHD risk profiles | Intervention Type: BEHAVIORAL; Name: Guidelines; Assigned to Arm(s): Guidelines

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metoclopramide to Aid Establishment of Breastfeeding After Delivery: a Randomized Controlled Trial
Brief Summary: Hypothesis: Early use of oral metoclopramide can hasten and improve the establishment of lactogenesis II in mothers after preterm and term deliveries.

The study hopes to show that metoclopramide can be effective to establish and sustain Lactogenesis II for both preterm and term infants.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Herbal galactagogue; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Herbal galactagogue | Intervention Type: DIETARY_SUPPLEMENT; Name: Herbal galactagogue; Assigned to Arm(s): Herbal galactagogue | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide (Maxolon) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide (Maxolon) | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metoclopramide (Maxolon); Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B, D
C: N/A
D: Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Frequent Hemodialysis Network: Daily Trial
Brief Summary: The Frequent Hemodialysis Network (FHN) Daily Trial is a randomized controlled trial recruiting subjects from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialysis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale.


Options:
A: Arm Label: Rosuvastatin 10mg; Type: EXPERIMENTAL; Interventions: Drug: 10mg Rosuvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 10mg Rosuvastatin; Assigned to Arm(s): Rosuvastatin 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Low normal pH (arterial pH 7.36-7.38); Type: ACTIVE_COMPARATOR; Interventions: Drug: ammonium chloride or sodium citrate/citric acid | Arm Label: High Normal pH (arterial pH 7.44-7.46); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium citrate/citratic acid | Intervention Type: DRUG; Name: ammonium chloride or sodium citrate/citric acid; Assigned to Arm(s): Low normal pH (arterial pH 7.36-7.38) | Intervention Type: DRUG; Name: Sodium citrate/citratic acid; Assigned to Arm(s): High Normal pH (arterial pH 7.44-7.46)
C: Arm Label: Conventional hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional hemodialysis | Arm Label: Frequent hemodialysis; Type: EXPERIMENTAL; Interventions: Device: Frequent hemodialysis | Intervention Type: DEVICE; Name: Conventional hemodialysis; Assigned to Arm(s): Conventional hemodialysis | Intervention Type: DEVICE; Name: Frequent hemodialysis; Assigned to Arm(s): Frequent hemodialysis
D: Arm Label: 1: low flux hemodialysis; Type: OTHER; Interventions: Procedure: low flux hemodialysis | Arm Label: 2 on-line hemodiafiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: on-line hemodiafiltration; Assigned to Arm(s): 2 on-line hemodiafiltration | Intervention Type: PROCEDURE; Name: low flux hemodialysis; Assigned to Arm(s): 1: low flux hemodialysis

Answer: C